Please login to the form below

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer

Renal cell carcinoma accounts for more than 431, 000 new cases and 179, 000 deaths each year. ... cell carcinoma (RCC), the most common type of kidney cancer in adults.

Latest news

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

for the adjuvant treatment of renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection, in adults. ... NICE’s decision is based on positive results from KEYNOTE-564, a multicentre,
EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

Vegzelma has been approved specifically for the treatment of metastatic breast cancer, non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or ... By attaching to vascular endothelial growth
Pfizer's 2021 revenue predictions soar to $82bn

its sales by 30%, driven by first-line use in advanced renal cell carcinoma.
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

of health-related quality of life in a phase 3 trial in first-line renal cell carcinoma (RCC) – the most common form of kidney cancer. ... We continue to see an increasing number of patients diagnosed with advanced renal cell carcinoma and remain
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

plus Merck &Co’s checkpoint inhibitor Keytruda for the first-line treatment of advanced renal cell carcinoma (RCC).

More from news
Approximately 16 fully matching, plus 155 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in
Charting a course for expansion

Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
Deal Watch March 2016

Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
Deal Watch December 2015

510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
Pharma deals during April 2014

Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). ... This was largely driven by the phase 2 autologous

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

New hires at Crescendo, Healx and Galecto

oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple. ... This experience will be crucial as we progress our pipeline
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
CytomX appoints Rachel Humphrey chief medical officer

Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
Bayer’s former oncology head Robert Rosen joins AP Pharma

During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the launch of Nexavar (sorafenib) for the treatment of renal cell

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Cell Carcinoma.
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
A stumble, but not a fall – what’s next for Opdivo?

and renal cell carcinoma (kidney cancer). ... Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower